Quantitative studies of allosteric effects by biointeraction chromatography: Analysis of protein binding for low-solubility drugs

Jianzhong Chen, David S. Hage

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

A new chromatographic method was developed for characterizing allosteric interactions between an immobilized binding agent and low-solubility compounds. This approach was illustrated by using it to characterize the interactions between tamoxifen and warfarin during their binding to the protein human serum albumin (HSA), with β-cyclodextrin being employed as a solubilizing agent for these drugs. It was confirmed in this work through several experiments that warfarin had a single binding site on HSA with an association equilibrium constant of (2-5) × 105 M-1 (average, 3.9 × 105 M-1) at 37 °C, in agreement with previous reports. It was also found that tamoxifen had a single major binding site on HSA, with an association equilibrium constant of (3-4) × 107 M -1 (average, 3.5 × 107 M-1) at 37 °C. When warfarin was used as a mobile-phase additive in competition studies with tamoxifen, this had a positive allosteric effect on tamoxifen/HSA binding, giving a coupling constant of 2.3 (±0.3). Competitive studies using tamoxifen as a mobile-phase additive indicated that tamoxifen had a negative allosteric effect on warfarin/HSA binding, providing a coupling constant of 0.79 (±0.03). A unique feature of the technique described in this report was its ability to independently examine both directions of the warfarin/tamoxifen allosteric interaction. This approach is not limited to warfarin, tamoxifen, and HSA but can also be used to study other solutes and binding agents.

Original languageEnglish (US)
Pages (from-to)2672-2683
Number of pages12
JournalAnalytical chemistry
Volume78
Issue number8
DOIs
StatePublished - Apr 15 2006

Fingerprint

Tamoxifen
Chromatography
Warfarin
Solubility
Serum Albumin
Pharmaceutical Preparations
Equilibrium constants
Binding Sites
Association reactions
Protein Binding
Cyclodextrins

ASJC Scopus subject areas

  • Analytical Chemistry

Cite this

Quantitative studies of allosteric effects by biointeraction chromatography : Analysis of protein binding for low-solubility drugs. / Chen, Jianzhong; Hage, David S.

In: Analytical chemistry, Vol. 78, No. 8, 15.04.2006, p. 2672-2683.

Research output: Contribution to journalArticle

@article{e3977071973c44108876bc620fbd2025,
title = "Quantitative studies of allosteric effects by biointeraction chromatography: Analysis of protein binding for low-solubility drugs",
abstract = "A new chromatographic method was developed for characterizing allosteric interactions between an immobilized binding agent and low-solubility compounds. This approach was illustrated by using it to characterize the interactions between tamoxifen and warfarin during their binding to the protein human serum albumin (HSA), with β-cyclodextrin being employed as a solubilizing agent for these drugs. It was confirmed in this work through several experiments that warfarin had a single binding site on HSA with an association equilibrium constant of (2-5) × 105 M-1 (average, 3.9 × 105 M-1) at 37 °C, in agreement with previous reports. It was also found that tamoxifen had a single major binding site on HSA, with an association equilibrium constant of (3-4) × 107 M -1 (average, 3.5 × 107 M-1) at 37 °C. When warfarin was used as a mobile-phase additive in competition studies with tamoxifen, this had a positive allosteric effect on tamoxifen/HSA binding, giving a coupling constant of 2.3 (±0.3). Competitive studies using tamoxifen as a mobile-phase additive indicated that tamoxifen had a negative allosteric effect on warfarin/HSA binding, providing a coupling constant of 0.79 (±0.03). A unique feature of the technique described in this report was its ability to independently examine both directions of the warfarin/tamoxifen allosteric interaction. This approach is not limited to warfarin, tamoxifen, and HSA but can also be used to study other solutes and binding agents.",
author = "Jianzhong Chen and Hage, {David S.}",
year = "2006",
month = "4",
day = "15",
doi = "10.1021/ac052017b",
language = "English (US)",
volume = "78",
pages = "2672--2683",
journal = "Analytical Chemistry",
issn = "0003-2700",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Quantitative studies of allosteric effects by biointeraction chromatography

T2 - Analysis of protein binding for low-solubility drugs

AU - Chen, Jianzhong

AU - Hage, David S.

PY - 2006/4/15

Y1 - 2006/4/15

N2 - A new chromatographic method was developed for characterizing allosteric interactions between an immobilized binding agent and low-solubility compounds. This approach was illustrated by using it to characterize the interactions between tamoxifen and warfarin during their binding to the protein human serum albumin (HSA), with β-cyclodextrin being employed as a solubilizing agent for these drugs. It was confirmed in this work through several experiments that warfarin had a single binding site on HSA with an association equilibrium constant of (2-5) × 105 M-1 (average, 3.9 × 105 M-1) at 37 °C, in agreement with previous reports. It was also found that tamoxifen had a single major binding site on HSA, with an association equilibrium constant of (3-4) × 107 M -1 (average, 3.5 × 107 M-1) at 37 °C. When warfarin was used as a mobile-phase additive in competition studies with tamoxifen, this had a positive allosteric effect on tamoxifen/HSA binding, giving a coupling constant of 2.3 (±0.3). Competitive studies using tamoxifen as a mobile-phase additive indicated that tamoxifen had a negative allosteric effect on warfarin/HSA binding, providing a coupling constant of 0.79 (±0.03). A unique feature of the technique described in this report was its ability to independently examine both directions of the warfarin/tamoxifen allosteric interaction. This approach is not limited to warfarin, tamoxifen, and HSA but can also be used to study other solutes and binding agents.

AB - A new chromatographic method was developed for characterizing allosteric interactions between an immobilized binding agent and low-solubility compounds. This approach was illustrated by using it to characterize the interactions between tamoxifen and warfarin during their binding to the protein human serum albumin (HSA), with β-cyclodextrin being employed as a solubilizing agent for these drugs. It was confirmed in this work through several experiments that warfarin had a single binding site on HSA with an association equilibrium constant of (2-5) × 105 M-1 (average, 3.9 × 105 M-1) at 37 °C, in agreement with previous reports. It was also found that tamoxifen had a single major binding site on HSA, with an association equilibrium constant of (3-4) × 107 M -1 (average, 3.5 × 107 M-1) at 37 °C. When warfarin was used as a mobile-phase additive in competition studies with tamoxifen, this had a positive allosteric effect on tamoxifen/HSA binding, giving a coupling constant of 2.3 (±0.3). Competitive studies using tamoxifen as a mobile-phase additive indicated that tamoxifen had a negative allosteric effect on warfarin/HSA binding, providing a coupling constant of 0.79 (±0.03). A unique feature of the technique described in this report was its ability to independently examine both directions of the warfarin/tamoxifen allosteric interaction. This approach is not limited to warfarin, tamoxifen, and HSA but can also be used to study other solutes and binding agents.

UR - http://www.scopus.com/inward/record.url?scp=33646140099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646140099&partnerID=8YFLogxK

U2 - 10.1021/ac052017b

DO - 10.1021/ac052017b

M3 - Article

C2 - 16615779

AN - SCOPUS:33646140099

VL - 78

SP - 2672

EP - 2683

JO - Analytical Chemistry

JF - Analytical Chemistry

SN - 0003-2700

IS - 8

ER -